Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours

Published: June 8, 2009
Abstract Views: 175
Untitled (): 0
PDF: 232
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Zoledronic acid (Zometa) is increasingly used to treat tumour-induced bone disease, and is also reported to have anti-angiogenic properties in vivo.1,2 In this study we have investigated the correlations between changes in the pro-angiogenic cytokine VEGF and markers of bone resorption in a cohort of patients with metastatic bone disease, following a single infusion of zoledronic acid.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Vincenzi, B., Santini, D., Holen, I., & Tonini, G. (2009). Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Hematology Meeting Reports (formerly Haematologica Reports), 2(3). https://doi.org/10.4081/hmr.v2i3.375